Development of antibodies for cancer therapy

Expert Opinion on Biological Therapy

Volumn 6, Issue 8, 2006, Pages 787-796

  Wilkins, D K ^b   Mayer, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NONE

Author keywords

ADEPT; Antivascular agents; Cancer therapy; Conjugated antibodies; Immunotoxins; Radioimmunotherapy; Unconjugated antibodies

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BEVACIZUMAB; BIOTIN; CETUXIMAB; GEMTUZUMAB OZOGAMICIN; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; RITUXIMAB; STREPTAVIDIN; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; VASCULAR TARGETING AGENT; CANCER VACCINE; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; HEAD AND NECK CANCER; HUMAN; IMMUNOGENICITY; LEUKEMIA; LYMPHOMA; RADIOIMMUNOTHERAPY; REVIEW; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COLORECTAL TUMOR; IMMUNOLOGY; METHODOLOGY; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIBODIES; BIOTIN; CANCER VACCINES; CHEMISTRY, PHARMACEUTICAL; COLORECTAL NEOPLASMS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTOXINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RADIOIMMUNOTHERAPY; STREPTAVIDIN;

EID: 33748093288     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.8.787     Document Type: Review

References (58)

1. SHIBUYA K, MATHERS CD, BOSCHI-PINTO C, LOPEZ AD, MURRAY CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer (2002) 2:37.
2. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
3. BYRD JC, KITADA S, FLINN IW et al.: The mechanism of tumour cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukaemia: evidence of caspase activation and apoptosis induction. Blood (2002) 99(3):1038-1043.
4. DI GAETANO N, CITTERA E, NOTA R et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. (2003) 171:1581-1587.
5. WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. (2003) 21:3940-3947.
6. SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
7. PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353:1659-1672.
8. ROMOND EH, PEREZ EA, BRYANT J et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl J. Med. (2005) 353:1673-1684. Adjuvant trastuzumab therapy increases survival in early HER2-positive breast cancer.
9. CRONE SA, ZHAO YY, FAN L et al.: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. (2002) 8:459-465.
10. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
11. BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354:567-578.
12. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342. The first antiangiogenesis therapy to increase survival in cancer patients.
13. SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599. American Society of Clinical Oncology (ASCO) Annual Meeting. Orlando, Florida, USA (13-17 May 2005).
14. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma. N. Engl. J. Med. (2003) 349(5):427-434.
15. OLINER J, MIN H, LEAL J et al.: Supression of angiogenesis and tumour growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 6(5):507-516.
16. ADAMS GP, TAI MS, MCCARTNEY JE et al.: Avidity-mediated enhancement of in vivo tumour targeting by single-chain Fv Dimers. Clin. Cancer Res. (2006) 12(5):1599-1605.
17. HAINSWORTH JD, SOSMAN JA, SPIGEL DR, EDWARDS DL, BAUGHMAN C, GRECO A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. (2005) 23(31):7889-7896.
18. MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 81:6851-6855.
19. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.
20. JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTER G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321:522-525. First report of humanised antibodies.
21. LONBERG N, TAYLOR LD, HARDING FA et al.: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 368:856-859.
22. GREEN LL, HARDY MC, MAYNARD-CURRIE CE et al.: Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat. Genet. (1994) 7:13-21.
23. ROWINSKY EK, SCHWARTZ GH, GOLLOB JA et al.: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. (2004) 22:3003-3015.
24. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA ma. Arthritis Rheum. (2003) 48(1):35-45.
25. MEASE PJ, GLADMAN DD, RITCHLIN CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(10):3279-3289.
26. KAMINSKI MS, TUCK M, ESTES J et al.: 1311-tositumornab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. (2005) 352:441-449.
27. GORDON LI, WITZIG T, MOLINA A et al.: Yrtrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma (2004) 5:98-101.
28. WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20:3262-3269.
29. 2 antibodies. Br. J. Cancer (1994) 70:521-525.
30. PEDLEY RB, HILL SA, BOXER GM et al.: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. (2001) 61:4716-4722. Preclinical results of RIT and antivascular therapy in xenografts.
31. SHEN S, FORERO A, LOBUGLIO AF et al.: Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. (2005) 46:642-651.
32. LARSON RA, SIEVERS EL, STADTMAUER EA et al.: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukaemia in first recurrence. Cancer (2005) 104(7):1442-1452.
33. MA D, HOPF CE, MALEWICZ AD et al.: Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. (2006) 12(8):2591-2596.
34. KOVTUN YV, AUDETTE CA, YE Y et al.: Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. (2006) 66(6):3214-3221.
35. KREITMAN RJ, SQUIRES DR, STETLER-STEVENSON M et al.: Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. (2005) 23:6719-6729.
36. OLSEN E, DUVIC M, FRANKEL A et al.: Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. (2001) 19(2):376-388.
37. BAGSHAWE KD: Antibody directed enzymes revive anticancer prodrugs concept. Br. J. Cancer (1987) 56:531-532.
38. BAGSHAWE KD, SPRINGER CJ, SEARLE F et al.: A cytotoxic agent can be generated selectively at cancer sites. Br. J. Cancer (1988) 58:700-703.
39. SENTER PD, SAULNIER MG, SCHREIBER GJ et al.: Anti-tumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA (1988) 85(13):4842-4846.
40. BAGSHAWE KD, SHARMA SK, SPRINGER CJ, ANTONIW P: Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial. Tumor Targeting (1995) 1:17-29.
41. BAGSHAWE KD, BEGENT RH: First clinical experience with ADEPT. Adv. Drug Deliv. Rev. (1996) 22:365-367.
42. NAPIER MP, SHARMA SK, SPRINGER CJ et al.: Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. (2000) 6:765-772.
43. SPRINGER CJ, ANTONIW P, BAGSHAWE KD, SEARLE F, BISSET GM, JARMAN M: Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. (1990) 33(2):677-681.
44. SPRINGER CJ, DOWELL R, BURKE PJ et al.: Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. (1995)38:5051-5065.
45. FRANCIS RJ, SHARMA SK, SPRINGER C et al.: A Phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer (2002) 87:600-607.
46. CHESTER KA, BEGENT RH, ROBSON L et al.: Phage libraries for generation of clinically useful antibodies. Lancet (1994) 343:455-456. First description of phage display technology for anti-CEA antibodies for the clinic.
47. BEGENT RH, VERHAAR MJ, CHESTER KA et al.: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. (1996) 2:979-984. First clinical use of a scFv antibody.
48. MAYER A, TSIOMPANOU E, O'MALLEY D et al.: Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin. Cancer Res. (2000)6:1711-1719.
49. MICHAEL NP, CHESTER KA, MELTON RG et al.: In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology (1996) 2:47-57.
50. MEDZIHRADSZKY KF, SPENCER DI, SHARMA SK et al.: Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology (2004) 14:27-37.
51. SPENCER DI, ROBSON L, PURDY D et al.: A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics (2002) 2:271-279.
52. MAYER A, SHARMA SK, TOLNER B et al.: Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer (2004) 90:2402-2410.
53. TANGRI S, MOTHE BR, EISENBRAUN J et al.: Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. (2005) 174:3187-3196.
54. SHARMA SK, PEDLEY RB, BHATIA J et al.: Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin. Cancer Res. (2005) 11:814-825. Preclinical results of ADEPT using a recombinant fusion protein in xenografts.
55. COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346:235-242. First report of survival advantage in a Phase III study from the addition of antibody to chemotherapy.
56. FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2004) 104:3064-3071.
57. MARCUS R, IMRIE K, BELCH A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105:1417-1423.
58. ELTER T, BORCHMANN P, SCHULZ H et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. (2005) 23:7024-7031.